Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
XBiotech Inc (XBIT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: XBIT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -15.72% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.37M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) - | Beta 0.97 | 52 Weeks Range 2.50 - 8.32 | Updated Date 06/29/2025 |
52 Weeks Range 2.50 - 8.32 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.29 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -13.78% | Return on Equity (TTM) -20.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -77061354 | Price to Sales(TTM) 12.23 |
Enterprise Value -77061354 | Price to Sales(TTM) 12.23 | ||
Enterprise Value to Revenue 24.05 | Enterprise Value to EBITDA -1.6 | Shares Outstanding 30487700 | Shares Floating 19852696 |
Shares Outstanding 30487700 | Shares Floating 19852696 | ||
Percent Insiders 35.07 | Percent Institutions 14.92 |
Upturn AI SWOT
XBiotech Inc
Company Overview
History and Background
XBiotech Inc. is a biopharmaceutical company focused on discovering and developing True Human antibodies for treating diseases. Founded with the aim of pioneering antibody therapies directly from human sources, the company has focused on developing therapies for oncology, inflammatory and infectious diseases.
Core Business Areas
- True Human Antibody Therapies: XBiotech focuses on developing antibody therapies directly derived from humans, aiming for higher efficacy and lower immunogenicity. Their pipeline targets various diseases with unmet medical needs.
Leadership and Structure
XBiotech Inc's leadership team consists of experienced professionals in the biopharmaceutical industry. The company operates with a research and development focus, structured to efficiently discover and develop antibody therapies.
Top Products and Market Share
Key Offerings
- Bermekimab: Bermekimab is a True Human antibody targeting interleukin-1 alpha (IL-1u03b1). It has been investigated for the treatment of various conditions, including advanced squamous cell carcinoma. Market share data is limited due to the drug being in development and not currently widely marketed. Competitors include companies developing therapies targeting IL-1 pathways and other cancer therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high innovation, intense competition, and stringent regulatory oversight. The market is driven by the increasing prevalence of chronic diseases, advancements in biotechnology, and the growing demand for novel therapies.
Positioning
XBiotech positions itself as an innovator in the True Human antibody field, aiming to develop therapies with improved efficacy and safety profiles. Their competitive advantage lies in their proprietary technology for discovering and developing human antibodies.
Total Addressable Market (TAM)
The TAM for antibody therapies targeting diseases like cancer and inflammatory conditions is substantial, potentially reaching billions of dollars. XBiotech is positioning itself to capture a portion of this market with its True Human antibody platform.
Upturn SWOT Analysis
Strengths
- Proprietary True Human antibody platform
- Focus on unmet medical needs
- Potential for improved efficacy and safety of therapies
Weaknesses
- High R&D costs
- Dependence on successful clinical trials
- Limited revenue generation from marketed products
- Small size relative to major competitors
Opportunities
- Partnerships and collaborations with larger pharmaceutical companies
- Expansion of pipeline into new therapeutic areas
- Positive clinical trial results leading to regulatory approval
- Increasing demand for antibody therapies
Threats
- Competition from established pharmaceutical companies
- Unsuccessful clinical trials
- Regulatory hurdles and delays
- Patent expirations
Competitors and Market Share
Key Competitors
- AMGN
- JNJ
- MRK
- BMY
- LLY
- ABBV
Competitive Landscape
XBiotech faces significant competition from larger, more established pharmaceutical companies. Their advantage lies in their True Human antibody technology, but they need to overcome challenges related to funding, clinical trial success, and regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to company status.
Future Projections: Future growth projections are unavailable without recent financial data and analyst coverage.
Recent Initiatives: Recent initiatives are difficult to ascertain without current public filings. Historically, the company focused on clinical development of Bermekimab and other antibody candidates.
Summary
XBiotech is a biopharmaceutical company with a focus on True Human antibody therapies. Their innovative approach could lead to breakthroughs in treating diseases with unmet medical needs. However, they face significant challenges including the need for clinical trial success, competition from larger companies, and securing adequate funding for research and development. Success will depend on demonstrating the efficacy and safety of their antibody candidates in clinical trials and navigating the regulatory landscape effectively. Recent visibility and public information is limited, impacting comprehensive analysis.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company websites
- SEC filings
- Industry reports
- Financial news sources
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About XBiotech Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2015-04-15 | Founder, President, CEO & Chairman Mr. John Simard | ||
Sector Healthcare | Industry Biotechnology | Full time employees 90 | Website https://www.xbiotech.com |
Full time employees 90 | Website https://www.xbiotech.com | ||
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.